Wheat Bread Study: Comparison of the Tolerance of Different Wheat Breads

Status Recruiting

Clinical Trial Summary

This study aims to assess the differences in tolerability of differently manufactured wheat breads in a target group of individuals with suspected wheat sensitivity. Additionally, it will be verified, if the absence of a response to oral exposure to defined bread types is associated with an absence of mucosal changes following CLE-assisted mucosal provocation with bread.

Clinical Trial Description

Nowadays, more than 20% of people in industrialized countries suffer from a food intolerance or food allergy, with wheat and gluten intolerances on the rise. Besides the well-known conditions celiac disease and wheat allergy, another clinical entity called non-celiac wheat sensitivity (NCWS) was described, which is not yet widely understood. Resulting from inconsistent diagnostic criteria the prevalence of NCWS varies from 0.5% to 13%. Due to the lack of validated diagnostic criteria and/or appropriate biomarkers for diagnosis of NCWS, it can currently only be suspected by exclusion of other diseases. To verify suspected NCWS, a double-blind placebo-controlled food challenge with wheat is recommended. A confocal laser endomicroscopy (CLE) with endoluminal provocation can also provide meaningful results on the individual intestinal mucosal response to specific allergens. Furthermore, it is as yet unclear whether NCWS is triggered by gluten, FODMAPs, or other wheat components such as α-amylase trypsin inhibitors. Bread manufacturing processes can influence the composition of bread and the presence of possible triggers of intolerance reactions. This study aims to investigate the tolerability of differently manufactured wheat breads in individuals with suspected NCWS. Additionally, we expect this approach to improve the currently inadequate diagnosis of NCWS, as well as to provide a better understanding of the underlying mechanisms. Therefore, individuals with suspected NCWS are included in the trial. Five different types of bread will be tested, including 3 differently manufactured wheat breads, a gluten free bread and a gluten free bread with added wheat flour. Aim of this part is to test a possible psychological factor in NCWS symptoms. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06152445
Study type	Interventional
Source	University of Hohenheim
Contact	Stephan C Bischoff, Prof.Dr
Phone	071145924101
Email	bischoff.stephan@uni-hohenheim.de
Status	Recruiting
Phase	N/A
Start date	November 2023
Completion date	June 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05555446` - Bovine Colostrum to Prevent Absorption of Gluten	Early Phase 1
Completed	`NCT02472704` - Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo	N/A
Completed	`NCT03775499` - Probiotic BL NCC 2705 and Gluten Sensitivity	N/A
Completed	`NCT05779358` - Gluten and (Extra-)Intestinal Symptoms in NCGS	N/A
Recruiting	`NCT05238545` - The Effect of Gluten-free Diet on Parkinsonism	N/A
Completed	`NCT04401956` - Bread Study: Comparison of the Tolerance of Spelt and Wheat Bread	N/A
Recruiting	`NCT06338891` - Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks
Recruiting	`NCT05644795` - Wheat-free Diet in the Treatment of Sjogren's Syndrome	N/A
Completed	`NCT04377061` - Anemia in Non-celiac Wheat Sensitivity
Completed	`NCT04077840` - Autoimmune Diseases and Serum Autoantibodies in NCWS and IBS Patients
Completed	`NCT04769180` - Extraintestinal Non Celiac Wheat Sensitivity
Not yet recruiting	`NCT06191432` - Tolerability of an Ancient Grain in Patients With Non-Celiac Wheat Sensitivity	N/A
Completed	`NCT04017585` - Identification of Gluten Sensitivity in Irritable Bowel Syndrome	N/A
Recruiting	`NCT02810301` - Efficacy of Probiotic ES1 for the Treatment of Non-Celiac Gluten Sensitivity	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.